A Novel Form of Methotrexate
IGF Oncology’s IGF-MTX shows promise in clinical trials for improved efficacy at lower dosages with the likelihood of enhanced therapeutic window and decreased toxicity in solid and liquid tumors for multiple indications.
By targeting IGF-1 receptors on cancer cells, IGF Oncology is developing novel conjugates that can help healthcare providers successfully address some of the most dangerous and aggressive cancers.
For more information about out current clinical trial please visit https://clinicaltrials.gov/ct2/show/NCT02045368
IGF Oncology, LLC, is a Minnesota company registered in Delaware.